DURHAM – Fortrea has agreed to pay about $45 million in cash for Worldwide Clinical Trials’ early-phase services business, adding three Texas research facilities to the Durham company’s clinical development network.

The companies announced the definitive agreement Sept. 2. The transaction has not closed and remains subject to necessary regulatory and license approvals, along with the companies entering certain services agreements, according to Fortrea’s acquisition announcement. The companies did not provide an expected closing date.

The business includes a 60,000-square-foot laboratory in Austin that operates under Good Laboratory Practice standards, a 200-bed clinical pharmacology unit in San Antonio that follows Good Clinical Practice standards and a biospecimen storage facility in Pflugerville. The assets support early-stage drug studies and laboratory analysis for both large- and small-molecule treatments.

Fortrea said bringing the clinical and bioanalytical operations under one owner would reduce handoffs between functions and expand the number and complexity of studies its network can handle. Those operational benefits remain expectations tied to a transaction that is still awaiting closing conditions.

Once the deal closes, the acquired operations will become part of Fortrea’s Clinical Pharmacology Services business. Fortrea already provides Phase I through Phase IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology, medical device and diagnostics companies.

Fortrea CEO Anshul Thakral called the purchase an investment in the front end of the company’s clinical development platform. Thakral, who joined Fortrea as CEO in August 2025, also serves on its board, according to his official company biography. Fortrea’s announcement linked the acquisition to expanded capacity, broader scientific capabilities and potential long-term value for shareholders.

Worldwide CEO Alistair Macdonald said the sale would allow his company to focus investment on a late-stage business spanning oncology, neuroscience, internal medicine and rare disease. Worldwide has more than 4,500 full-time employees in more than 70 countries, but the companies did not disclose how many workers are attached to the assets being sold.

The companies intend to use a strategic alliance and related agreements to maintain customer support, active studies and employee continuity during the transition. Worldwide will continue supporting Phase I work through its broader clinical development capabilities and external site network.

Barclays is serving as Fortrea’s financial adviser, and Mintz is its legal counsel. BroadOak Partners is Worldwide’s financial adviser, while Greenberg Traurig is its legal counsel. Independent coverage from Fierce Biotech and the Triangle Business Journal also reported the $45 million price and the three Texas facilities.

The companies did not disclose revenue or earnings contributions from the acquired unit, a financing source, the number of employees who could transfer or any change to Fortrea’s Durham workforce or North Carolina facilities.

 

 

 

 

 

Sources:
Fortrea acquisition announcement: https://ir.fortrea.com/news-releases/news-release-details/fortrea-acquire-clinical-pharmacology-unit-and-bioanalytical
Worldwide acquisition announcement: https://www.worldwide.com/newsroom/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials/
Fortrea CEO biography: https://www.fortrea.com/about-us/meet-our-team/anshul-thakral
Fierce Biotech transaction report: https://www.fiercebiotech.com/cro/fortrea-boosts-early-phase-platform-45-million-cro-acquisition
Triangle Business Journal transaction report: https://www.bizjournals.com/triangle/news/2026/09/04/fortrea-buys-worldwide-clinical-early-phase-unit.html
Image credit: Photo and logo courtesy of Fortrea. Anshul Thakral, chief executive officer.